Elysium Therapeutics, Inc.

Lyons, CO

UEI
CQ2LJLATAKH9
CAGE
6Y1G3, 0QD58
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Other NAICS codes in SAM.gov
SAM.gov registration date
Physical address
57 Ogallala Rd, Lyons, CO 80540, USA
Website
elysiumrx.com
Founded
2013
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Novel opioid prodrugs with oral overdose protection: minimizing cost-of-goods R43DA046302 National Institute on Drug Abuse (NIH) $274,150
Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction R01DA046102 National Institute on Drug Abuse (NIH) $6,876,933
Unprecedented diversion-/abuse-resistance: molecular deactivation of opioid drugs R44DA037908 National Institute on Drug Abuse (NIH) $4,389,944
BIO-activated opioid drugs with unprecedented oral and non-oral abuse-resistance R44DA037900 National Institutes of Health $1,761,961

Quick answers

Is Elysium Therapeutics, Inc. registered in SAM.gov?

Yes. Elysium Therapeutics, Inc.'s SAM.gov registration is active through November 5, 2026.

What is Elysium Therapeutics, Inc.'s most recent federal award?

Elysium Therapeutics, Inc.'s most recent federal grant award is Novel opioid prodrugs with oral overdose protection: minimizing cost-of-goods (R43DA046302), from National Institute on Drug Abuse (NIH), on June 15, 2018.

On GovTribe

See Elysium Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login